Clinical Trials Logo

Acral Lentiginous Malignant Melanoma clinical trials

View clinical trials related to Acral Lentiginous Malignant Melanoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT01395121 Completed - Clinical trials for Acral Lentiginous Malignant Melanoma

A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread

NICAM
Start date: December 2009
Phase: Phase 2
Study type: Interventional

The aim of this study is to see if a drug called nilotinib (Tasigna®) is effective in the treatment of patients with a rare group of acral and mucosal melanomas that have a change (mutation) in a protein called cKIT. Nilotinib interferes with signalling inside cells with this mutation and it is believed that this may lead to shrinkage of tumours. Acral melanomas are found on the palms and soles and mucosal melanomas start inside body cavities rather than on the skin.

NCT ID: NCT01120275 Active, not recruiting - Recurrent Melanoma Clinical Trials

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

Start date: October 2010
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with stage IV melanoma. Gamma-secretase/Notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00577382 Active, not recruiting - Clinical trials for Acral Lentiginous Malignant Melanoma

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Start date: August 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate how effective SU011248 works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region. SU011248 is a protein-tyrosine kinase inhibitor and acts as a c-kit inhibitor drug. It is believed to work by blocking signals on certain cancer cells which allow the malignant cells to multiply and spread due to a change in the genetic make up of the cancer cell.

NCT ID: NCT00470470 Completed - Recurrent Melanoma Clinical Trials

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Start date: April 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well imatinib mesylate works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00243061 Completed - Recurrent Melanoma Clinical Trials

AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma

Start date: January 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well AZD2171 works in treating patients with recurrent or stage IV melanoma. AZD2171 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.